Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 2050 of 2228 entries
View as:

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Phase: N/A Priority: Normal
NCT ID: NCT02414958 Org: User:
Start: 06/30/15 End: 10/23/17 Due: 10/23/18

Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg

Phase: N/A Priority: Normal
NCT ID: NCT00350207 Org: User:
Start: 07/31/06 End: - Due: -

Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan

Phase: N/A Priority: Normal
NCT ID: NCT01108796 Org: User:
Start: 09/30/08 End: 09/30/09 Due: 09/30/10

Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir

Phase: N/A Priority: Normal
NCT ID: NCT01785160 Org: User:
Start: 02/28/13 End: 03/31/13 Due: 03/31/14

Observational Study of METALYSE® in Patients With Acute Myocardial Infarction In Russian Federation

Phase: N/A Priority: Normal
NCT ID: NCT02191670 Org: User:
Start: 04/30/05 End: - Due: -

BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

Phase: N/A Priority: Normal
NCT ID: NCT02871635 Org: User:
Start: 09/28/16 End: 05/13/19 Due: 05/13/20

This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood

Phase: N/A Priority: Normal
NCT ID: NCT03403439 Org: User:
Start: 05/03/18 End: 07/20/18 Due: 07/20/19

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Phase: N/A Priority: Normal
NCT ID: NCT01728324 Org: User:
Start: 11/30/12 End: 01/31/15 Due: 01/31/16

In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02260024 Org: User:
Start: 10/31/05 End: - Due: -

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse

Phase: N/A Priority: Normal
NCT ID: NCT01690624 Org: User:
Start: 09/13/12 End: 05/21/18 Due: 05/21/19

A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Phase: N/A Priority: Normal
NCT ID: NCT05278104 Org: User:
Start: 09/14/23 End: 10/30/24 Due: 10/30/25

An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities

Phase: N/A Priority: Normal
NCT ID: NCT03843892 Org: User:
Start: - End: - Due: -

Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Healthy Recreational Sports People

Phase: N/A Priority: Normal
NCT ID: NCT02182934 Org: User:
Start: 11/30/99 End: - Due: -

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT03817463 Org: User:
Start: 04/15/19 End: 12/10/21 Due: 12/10/22

Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02342717 Org: User:
Start: 01/31/15 End: 03/31/15 Due: 03/31/16

Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change

Phase: N/A Priority: Normal
NCT ID: NCT06053541 Org: User:
Start: 04/01/21 End: 07/01/21 Due: 07/01/22

A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body

Phase: N/A Priority: Normal
NCT ID: NCT05515588 Org: User:
Start: 09/19/22 End: 11/17/22 Due: 11/17/23

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Phase: N/A Priority: Normal
NCT ID: NCT03165240 Org: User:
Start: 10/05/17 End: 05/07/20 Due: 05/07/21

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

Phase: N/A Priority: Normal
NCT ID: NCT00479401 Org: User:
Start: 05/31/07 End: - Due: -

Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT02226939 Org: User:
Start: 09/30/02 End: - Due: -

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Phase: N/A Priority: Normal
NCT ID: NCT01466660 Org: User:
Start: 12/13/11 End: 04/12/19 Due: 04/12/20

Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02172573 Org: User:
Start: 04/30/99 End: - Due: -

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

Phase: N/A Priority: Normal
NCT ID: NCT01257230 Org: User:
Start: 12/31/10 End: 12/31/13 Due: 12/31/14

Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT00543803 Org: User:
Start: 02/28/06 End: - Due: -

Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT02172469 Org: User:
Start: 05/31/01 End: - Due: -